Viridian Therapeutics downgraded to Neutral from Buy at Ladenburg

Ladenburg downgraded Viridian Therapeutics to Neutral from Buy without a price target following the Q1 report. The most notable update is that since the recent Type C meeting, the FDA is now requiring Viridian to run a relatively large safety study, the analyst tells investors in a research note. The firm cites the increased likelihood of further delays given the real world evidence on the leading thyroid eye disease treatment, Tepezza, and increased expectation for a more difficult development than Viridian and investors may be expecting for the downgrade.